Esoterix Demonstrates Steady Expansion, Rapid Growth.

Business Editors/Health/Medical Writers

AUSTIN, Texas--(BUSINESS WIRE)--June 6, 2003

Esoterix, Inc. continues to grow their business 25 percent by adding a suite of new facilities, resources, products and in turn, revenue. Esoterix, a fast growing healthcare services company offering technology-based laboratory services and information solutions to healthcare providers, announces the addition of two Clinical Trials Services facilities, three first-to-market assays, five vice presidents, four MDs and three PhD-level scientists -- all within the new fiscal year.

"Our high rate of growth and continued investment in the health services industry has positioned us to provide superior service to our customers in the laboratory services, oncology and clinical trials markets," said James McClintic, President and Chief Executive Officer of Esoterix. "We continue to focus our efforts on these three key market segments, enabling us to provide high science and significant revenue growth, well above the current market."

In an effort to offer customers superior service, two new clinical trials facilities were specifically designed to handle the demands of bio-pharmaceutical research in oncology, infectious disease, endocrinology, molecular genetics, coagulation, and allergy and asthma. Esoterix's Clinical Trials Services facilities in East Windsor, New Jersey and Groningen, The Netherlands are dedicated to providing central safety laboratory testing resources for pharmaceutical and biotechnology companies in the drug discovery and development stages. Esoterix's central safety laboratory services ensure the highest level of laboratory safety using an automated, redundant technology to safeguard precision and deliver uninterrupted results. Additionally, the new facilities provide a regional resource to customers such as high-end cell analysis and complete ELISA testing services.

As the facilities and services expand, the Esoterix scientific staff members are growing in numbers as well. Joining the ranks of existing Esoterix industry renowned scientists are Tim Alcorn, PhD, Perry Chan, PhD and Russell Grant, PhD. Debra Nelson, MD, Ronald Thomason, MD and Patricia Kandalaft, MD have also been added to the scientific staff. To support this steady and rapid growth, sales and marketing teams have added three new vice presidents of sales -- Robert Walker, William Briggs and William Crawford; a vice president of marketing -- Steve Lundy; and a vice president of managed Care -- Doug Masters. Together with the veterans at Esoterix, this team will implement the innovative strategies needed to keep Esoterix ahead of the industry.

Three new assays were developed by Esoterix and released in the areas of diabetes and sexually transmitted diseases. MODYdetX(SM) is the first test in its category to help provide a definitive diagnosis in adolescent patients with MODY-3, a form of non-insulin dependent diabetes. Microalbumin Plus(TM), exclusive to Esoterix, detects protein in the urine up to four years earlier than currently available tests. This test enables physicians to diagnose the onset of kidney disease earlier and with much greater accuracy. HPV TriTect(SM) allows for Human Papilloma Virus detection and identification along with GC/Chlamydia from a single specimen. These first-to-market assays compliment a diverse product offering of over 1,800 existing assays created to provide physicians and laboratorians with the most innovative high science methods to positively impact patient care.

"We continue to look to the future of the laboratory industry and provide the research and resources needed to improve medicine," said McClintic. "More importantly, we will continue to invest and grow the company to improve the lives of patients."

For more information log onto www.esoterix.com.